A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
A phase 2 trial of Talquetamab in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events is a phase 2 interventional study registered as NCT06500884 by Janssen Research & Development, LLC, with 210 participants planned, started 2024-08-26 and due to reach its primary completion in 2030-05-30. Interventions recorded: Talquetamab, Prophylaxis A, Prophylaxis B, Prophylaxis C, Prophylaxis D. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Shares Johnson & Johnson, Multiple myeloma.
- TrialA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Johnson & Johnson, Multiple myeloma.